RC
Ryan Cohlhepp
President and COODirector

Ryan Cohlhepp insider trades: Bicara Therapeutics (BCAX) stock sales

President and COO, Bicara Therapeutics Last trade Aug 10, 2026 11 Form 4 filings
$2.7M
Sold, last 12 months
8 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2025
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ryan reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 10, 2026BCAX↓ Sell$525K
Jul 9, 2026BCAX↓ Sell$833K
Apr 15, 2026BCAX↓ Sell$288K
Mar 16, 2026BCAX↓ Sell$246K
Mar 3, 2026BCAX↓ Sell$316K
Jan 15, 2026BCAX↓ Sell$3K
Dec 15, 2025BCAX↓ Sell$234K
Nov 21, 2025BCAX↓ Sell$226K
Oct 15, 2025BCAX↓ Sell$227K
Oct 7, 2025BCAX↓ Sell$912K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BCAX insiders

Open-market trades in the last 12 months

About Ryan Cohlhepp's insider trades

Ryan Cohlhepp is President and COO at Bicara Therapeutics (BCAX). Since Oct 7, 2025, Ryan has reported no open-market purchases and 10 sales worth $3.8M on SEC Form 4. In the last 12 months: 8 sales ($2.7M).

Their filings also include option exercises (9 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCAX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.